Technical Analysis for CGEN - Compugen Ltd.

Grade Last Price % Change Price Change
grade B 15.86 -2.58% -0.42
CGEN closed down 2.58 percent on Friday, July 10, 2020, on 52 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical CGEN trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
Upper Bollinger Band Touch Strength 0.00%
Up 3 Days in a Row Strength -2.58%
Up 4 Days in a Row Strength -2.58%
Up 5 Days in a Row Strength -2.58%
NR7 Range Contraction -0.44%
Inside Day Range Contraction -0.44%
Up 3 Days in a Row Strength -0.44%
Up 4 Days in a Row Strength -0.44%
MACD Bullish Signal Line Cross Bullish 0.25%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Compugen Ltd., a therapeutic product discovery company, engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company's therapeutic proteins pipeline includes CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-15021, a novel fusion protein for the treatment of multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases; CGEN-15091, a novel fusion protein for the treatment of multiple sclerosis and autoimmune diseases; CGEN-15031, a fusion protein candidate to treat multiple sclerosis; and CGEN-15051, a fusion protein candidate for the treatment of rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, a membrane protein target for the treatment of cancer; CGEN-15022 membrane protein for the treatment of multiple cancers; CGEN-671, a novel drug target for the treatment of multiple epithelial tumors; and CGEN-928 drug target for the treatment of multiple myeloma. Compugen Ltd. was founded in 1993 and is headquartered in Tel Aviv, Israel.
Medicine Biopharmaceutical Cancer Medical Specialties Life Sciences Immunology Treatment Of Cancer Antibodies Cancers Autoimmune Diseases Antibody Multiple Sclerosis Rheumatoid Arthritis Multiple Myeloma Autoimmunity Monoclonal Antibody Autoimmune Disorders Compugen Treatment Of Multiple Sclerosis Antibody Therapy Fusion Protein

Is CGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.85
52 Week Low 2.9601
Average Volume 1,431,846
200-Day Moving Average 8.96
50-Day Moving Average 14.60
20-Day Moving Average 15.27
10-Day Moving Average 15.31
Average True Range 1.09
ADX 12.21
+DI 25.08
-DI 16.12
Chandelier Exit (Long, 3 ATRs ) 13.89
Chandelier Exit (Short, 3 ATRs ) 15.96
Upper Bollinger Band 16.64
Lower Bollinger Band 13.91
Percent B (%b) 0.71
BandWidth 17.89
MACD Line 0.42
MACD Signal Line 0.36
MACD Histogram 0.059
Fundamentals Value
Market Cap 810.96 Million
Num Shares 51.1 Million
EPS -0.67
Price-to-Earnings (P/E) Ratio -23.67
Price-to-Sales 1330.24
Price-to-Book 3.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.23
Resistance 3 (R3) 17.35 17.02 17.00
Resistance 2 (R2) 17.02 16.67 16.96 16.92
Resistance 1 (R1) 16.44 16.46 16.28 16.32 16.85
Pivot Point 16.11 16.11 16.03 16.05 16.11
Support 1 (S1) 15.53 15.76 15.37 15.41 14.87
Support 2 (S2) 15.20 15.55 15.14 14.80
Support 3 (S3) 14.62 15.20 14.72
Support 4 (S4) 14.50